Business Context and Reporting Period
This Form 8-K Current Report was filed by IMMUNIC, INC. on March 16, 2022, covering events occurring on March 10, 2022, and March 15, 2022. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol IMUX.
Key Financial Metrics
This filing is a current report regarding corporate governance and executive agreements. It does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial performance data is disclosed in this document.
Material Changes and Corporate Actions
- Executive Chairman Agreement Extension: On March 15, 2022, the Company entered into a third addendum with Dr. Duane Nash to extend his Executive Chairman Agreement term through December 31, 2022.
- Compensation for Dr. Nash: In connection with the extension, Dr. Nash received a one-time option award to purchase 75,000 shares of common stock. These options vest monthly commencing April 10, 2022.
- CFO Appointment: On March 10, 2022, Glenn Whaley was appointed Chief Financial Officer, having previously served as Principal Financial and Accounting Officer.
- Compensation for Mr. Whaley: Mr. Whaley received a one-time option award to purchase 40,000 shares of common stock. Vesting is structured as 25% on March 10, 2023, with the remainder vesting monthly thereafter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is strictly limited to reporting the entry into material definitive agreements and the appointment of a principal officer.
Key Facts for Investor Verification
- Verify the vesting schedules and exercise prices for the 75,000 options granted to Dr. Nash and the 40,000 options granted to Mr. Whaley in the attached Exhibit 10.1.
- Confirm the total outstanding share count and potential dilution impact from these new option grants.
- Review the full text of the Addendum No. 3 to the Employment Agreement (Exhibit 10.1) for any additional terms or conditions not summarized in the 8-K.
- Check subsequent filings for the Company's next scheduled financial report to obtain actual revenue and liquidity data, as none is present here.